DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for juvenile idiopathic arthritis — screening already-approved drugs against its 43-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJuvenile idiopathic arthritis maps to a 43-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for juvenile idiopathic arthritis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
macrophage migration inhibitory factor (MIF) — MIF is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ipadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9JIT · 1.08 Å · ligand ISOPROPYL ALCOHOL (IPA). Experimental structure, not a prediction.
What the evidence adds up to
Juvenile idiopathic arthritis is a heterogeneous group of arthritides developing before age 16 with no recognised cause. In North America and Europe, the systemic subtype accounts for 5% to 15% of diagnosed children. The 2021 American College of Rheumatology guideline addressed therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. A 2021 review noted that treatment has evolved over the last two decades, with clinical trials directed at more specific therapeutics based on discoveries about disease biology, and that advances in immune system research and the introduction of biologic drugs in the twenty-first century have given paediatric rheumatologists many more medications.
The American College of Rheumatology pediatric response criteria, developed in 1997, became the primary outcome measures in therapeutic trials. Preliminary definitions of flare and remission were subsequently added. Investigators have sought to determine whether measures used in adult rheumatoid arthritis might have utility in juvenile idiopathic arthritis. As pathogenesis becomes better understood, biomarkers have significant potential as outcome measures. Recent reports on health-related quality of life in large cohorts are important in guiding investigators towards areas most in need of improved treatment.
A 2015 review described recent success of targeted therapy in systemic juvenile idiopathic arthritis and stated that a direct link between diagnosis and therapy is required for further progress. Elucidation of pathogenic immune subsets was considered relevant to this endeavour, along with platforms that may help revolutionise discovery of the elusive target. The 2012 review summarised clinical manifestations, pathogenesis, treatment, and prognosis of systemic juvenile idiopathic arthritis, and reviewed macrophage activation syndrome as one of the most interesting and feared complications.
What is still missing is the precise identification of pathogenic immune subsets that would allow a direct diagnostic-therapeutic link, the validation of biomarkers as outcome measures, and the design of trials that can keep pace with improved understanding of disease pathogenesis. Funding for such stratified approaches and for long-term outcome studies in large cohorts remains limited.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Rheumatology · 2007 · 46 citations
Measuring clinical response and remission in juvenile idiopathic arthritis
AbstractPURPOSE OF REVIEW: The increasing availability of new medications for the treatment of juvenile idiopathic arthritis has made the accurate assessment of treatment outcomes critically important. The purpose of this review is to describe recent investigations focused on the development of new outcome measures in the domains of disease activity and joint damage, and to summarize recently published data within the area of health-related quality of life. RECENT FINDINGS: Since the development of the preliminary definition of disease improvement in 1997, the American College of Rheumatology pediatric response criteria have become the primary outcome measures in therapeutic trials in juvenile idiopathic arthritis. Additional definitions, including preliminary definitions of flare and remission have subsequently been added. Investigations have also sought to determine whether measures currently in use in adult rheumatoid arthritis might have utility in juvenile idiopathic arthritis. As the pathogenesis of juvenile idiopathic arthritis becomes better understood, biomarkers have significant potential as outcome measures. Lastly, recent reports regarding the health-related quality of life in large cohorts of children with juvenile idiopathic arthritis are important in guiding investigators towards areas most in need of improved treatment. SUMMARY: Significant progress has been made in the measurement of outcomes in juvenile idiopathic arthritis. Outcome measures will continue to be designed and tested to keep pace with the development of new therapies and the improved understanding of the disease pathogenesis.
AbstractCME Educational Objectives 1. Become familiar with the clinical presentation, differential diagnosis and potential complications of systemic juvenile idiopathic arthritis. 2. Understand what is known about the pathogenesis of systemic juvenile idiopathic arthritis and role of inflammatory cytokines in this disease. 3. Know the available treatments and current algorithm for treatment escalation in systemic juvenile idiopathic arthritis. Systemic juvenile idiopathic arthritis is a subtype of juvenile idiopathic arthritis, according to the recent International League of Associations for Rheumatology diagnostic criteria. 1 In North America and Europe, systemic juvenile idiopathic arthritis accounts for 5% to 15% of children diagnosed with juvenile idiopathic arthritis, although the disease is seen worldwide. 2 This review will summarize the clinical manifestations, pathogenesis, treatment, and prognosis of systemic juvenile idiopathic arthritis. It will also review one of the most interesting and feared complications of the disease, macrophage activation syndrome.
Expert Opinion on Orphan Drugs · 2015 · 2 citations
Using a theragnostic approach in juvenile idiopathic arthritis
AbstractIntroduction: Central to the concept of theragnostics is the elegant aim of precision medicine from the fusion of therapy and diagnostics. Recent advances in the field of juvenile idiopathic arthritis clinical therapy points towards a step forward in the aspect of targeted therapy, particularly in the context of systemic juvenile idiopathic arthritis.Areas covered: Juvenile idiopathic arthritis is a complex set of heterogenous diseases. Precision medicine will serve to dissect through this heterogeneity to provide targeted therapy for patients. This review will serve to educate the reader on recent success of targeted therapy in systemic juvenile idiopathic arthritis and how the field is impacted.Expert opinion: A direct link between diagnosis and therapy is required for further progress in targeted therapy of juvenile idiopathic arthritis. Elucidation of pathogenic immune subsets is relevant to this endeavor and the platforms that may help revolutionize the discovery of the elusive target.
Arthritis und Rheuma · 2023 · 0 citations · open access
2021 ACR Guideline zur Therapie der Oligoarthritis, Temporomandibular (TMG)-Arthritis und systemischen JIA (sJIA)
AbstractOnel KB, Horton DB, Lovell DJ et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol 2022; 74(4): 553–569. doi: 10.1002/art.42037. Epub 2022 Mar 1. PMID: 35233993.
Journal of Pharmaceutical Research International · 2021 · 0 citations · open access
Overview on Juvenile Idiopathic Arthritis: A Review
AbstractJuvenile idiopathic arthritis (JIA) is a broad term that refers to a clinically heterogeneous group of arthritis that develops before the age of 16 and has no recognized cause. JIA treatment has evolved during the last two decades. Clinical trials research has been directed at more specific therapeutics based on what has been discovered about the biology of disease. Pediatric rheumatologists now have many more medications to offer patients, with the expectation that their disease will be managed, thanks to advances in immune system research and the introduction of biologic drugs in the twenty-first century. Continuing development in these biological agents and discoveries new drugs as long as developing current gene analysis techniques is the best method to treat JIA and provide best quality of life.
AbstractA self-help guide for youth, Juvenile Arthritis: The Ultimate Teen Guide is also useful to family members, friends, and caregivers of those suffering from the disease. Author Kelly Rouba has prepared a truly comprehensive resource without making it overwhelming, in order to help those who have the disease lead the best life possible. As someone diagnosed with a severe form of juvenile arthritis at the age of two, Rouba is very familiar with how difficult—physically and emotionally—it can be to live with this chronic illness. Readers get an overview of juvenile arthritis from the point of view of teenagers and their parents, and the book also includes discussions related to diagnosis, symptoms of the disease, its history, and various related conditions. Treatment options are also provided, as well as tips on how to adapt to life with the disease including exercise, diet and therapy. A list of applicable Web sites and other helpful resources is included at the end of most chapters.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
